Although RNA binding–based regulatory mechanisms are hard to study in vivo, it will be interesting to investigate if other small molecules, either folate metabolism-related or not, are capable of modulating the moonlighting functions of TYMS, DHFR, and SHMT and if there are cancer-specific mechanistic differences that can be exploited further for antitumor therapy. This evidence concerns the gene SHMT2 and cancer.